ABL1 and acute lymphoblastic leukemia: Here we demonstrate that JNK plays an important role in the maintenance of Ph+ B-ALL and it is an effective target for combination therapy of BCR-ABL+ B-ALL together with BCR-ABL TKI dasatinib.